• The Korean Journal of Pain
• /
• 제34권1호
• /
• pp.4-18
• /
• 2021

Except for carbamazepine for trigeminal neuralgia, gabapentinoid anticonvulsants have been the standard for the treatment of neuropathic pain. Pregabalin, which followed gabapentin, was developed with the benefit of rapid peak blood concentration and better bioavailability. Mirogabalin besylate (DS-5565, Tarlige®) shows greater sustained analgesia due to a high affinity to, and slow dissociation from, the α2δ-1 subunits in the dorsal root ganglion (DRG). Additionally, it produces a lower level of central nervous system-specific adverse drug reactions (ADRs), due to a low affinity to, and rapid dissociation from, the α2δ-2 subunits in the cerebellum. Maximum plasma concentration is achieved in less than 1 hour, compared to 1 hour for pregabalin and 3 hours for gabapentin. The plasma protein binding is relatively low, at less than 25%. As with all gabapentinoids, it is also largely excreted via the kidneys in an unchanged form, and so the administration dose should also be adjusted according to renal function. The equianalgesic daily dose for 30 mg of mirogabalin is 600 mg of pregabalin and over 1,200 mg of gabapentin. The initial adult dose starts at 5 mg, given orally twice a day, and is gradually increased by 5 mg at an interval of at least a week, to 15 mg. In conclusion, mirogabalin is anticipated to be a novel, safe gabapentinoid anticonvulsant with a greater therapeutic effect for neuropathic pain in the DRG and lower ADRs in the cerebellum.

• 대한임상검사과학회지
• /
• 제36권1호
• /
• pp.13-18
• /
• 2004

This study was designed to establish working range for reoportable range in own laboratory in order to cover the upper and lower limits of the range in test method. We experimented ten times during 10 days for setting of reportable range with between run for method evaluation. It is generally assumed that the analytical method produces a linear response and that the test results between those upper and lower limits are then reportable. CLIA recommends that laboratories verify the reportable range of all moderate and high complexity tests. The Clinical Laboratory Improvement Amendments(CLIA) and Laboratory Accreditation Program of the Korean Society for Laboratory Medicine states reportable range is only required for "modified" moderately complex tests. Linearity requirements have been eliminated from the CLIA regulations and from others accreditation agencies, many inspectors continue to feel that linearity studies are a part of good lab practice and should be encouraged. It is important to assess the useful reportable range of a laboratory method, i.e., the lowest and highest test results that are reliable and can be reported. Manufacturers make claims for the reportable range of their methods by stating the upper and lower limits of the range. Instrument manufacturers state an operating range and a reportable range. The commercial linearity material can be used to verify this range, if it adequately covers the stated linear interval. CLIA requirements for quality control, must demonstrate that, prior to reporting patient test results, it can obtain the performance specifications for accuracy, precision, and reportable range of patient test results, comparable to those established by the manufacturer. If applicable, the laboratory must also verify the reportable range of patient test results. The reportable range of patient test results is the range of test result values over which the laboratory can establish or verify the accuracy of the instrument, kit or test system measurement response. We need to define the usable reportable range of the method so that the experiments can be properly planned and valid data can be collected. The reportable range is usually defined as the range where the analytical response of the method is linear with respect to the concentration of the analyte being measured. In conclusion, experimental results on reportable range using concentrated control sample and zero calibrators covering from highest to lowest range were salicylate $8.8{\mu}g/dL$, phenytoin $0.67{\mu}g/dL$, phenobarbital $1.53{\mu}g/dL$, primidone $0.16{\mu}g/dL$, theophylline $0.2{\mu}g/dL$, vancomycine $1.3{\mu}g/dL$, valproic acid $3.2{\mu}g/dL$, digitoxin 0.17ng/dL, carbamazepine $0.36{\mu}g/dL$ and acetaminophen $0.7{\mu}g/dL$ at minimum level and salicylate $969.9{\mu}g/dL$, phenytoin $38.1{\mu}g/dL$, phenobarbital $60.4{\mu}g/dL$, primidone $24.57{\mu}g/dL$, theophylline $39.2{\mu}g/dL$, vancomycine $83.65{\mu}g/dL$, valproic acid $147.96{\mu}g/dL$, digitoxin 5.04ng/dL, carbamazepine $19.76{\mu}g/dL$, acetaminophen $300.92{\mu}g/dL$ at maximum level.

• Environmental Engineering Research
• /
• 제22권3호
• /
• pp.329-338
• /
• 2017

Nanofiltration (NF) technology is a membrane-based separation process, which has been pervasively used as the high-effective technology for drinking water treatment. In this study, a kind of composite polyamide NF thin film is selected to investigate the removal efficiencies and mechanisms of 14 trace drugs, which are commonly and frequently detected in the drinking water. The results show that the removal efficiencies of most drugs are quite high, indicating the NF is an effective technology to improve the quality of drinking water. The removal efficiencies of carbamazepine, acetaminophen, estradiol, antipyrine and isopropyl-antipyrine in ultrapure water are $78.8{\pm}0.8%$, $16.4{\pm}0.5%$, $65.4{\pm}1.8%$, $71.1{\pm}1.5%$ and $89.8{\pm}0.38%$, respectively. Their rejection rates increase with the increasing of their three-dimensional sizes, which indicates that the steric exclusion plays a significant role in removal of these five drugs. The adsorption of estradiol with the strongest hydrophobicity has been studied, which indicates that adsorption is not negligible in terms of removing this kind of hydrophobic neutral drugs by NF technology. The removal efficiencies of indomethacin, diclofenac, naproxen, ketoprofen, ibuprofen, clofibric acid, sulfamethoxazole, amoxicillin and bezafibrate in ultrapure water are $81{\pm}0.3%$, $86.3{\pm}0.5%$, $85.7{\pm}0.4%$, $93.3{\pm}0.3%$, $86.6{\pm}2.5%$, $90.6{\pm}0.4%$, $59.7{\pm}1.7%$, $80.3{\pm}1.4%$ and $80{\pm}0.5%$, respectively. For these nine drugs, their rejection rates are better than the above five drugs because they are negatively charged in ultrapure water. Meanwhile, the membrane surface presents the negative charge. Therefore, both electrostatic repulsion and steric exclusion are indispensable in removing these negatively charged drugs. This study provides helpful and scientific support of a highly effective water treatment method for removing drugs pollutants from drinking water.

• 한국환경과학회지
• /
• 제18권3호
• /
• pp.245-254
• /
• 2009

In recent years, environmental pollution by phannaceuticals and personal care products (PPCPs) in the aquatic environment is of great concern worldwide. Recent studies have been reported to occur in a variety of environmental organisms such as surface, drinking and ground water, soils, sediments and hospitals. The purpose of this study was to evaluate the occurrence and environmental behavior of fourteen human PPCPs in surface waters of Mankyung River in South Korea. We were conducted to field survey for water quality and PPCPs analysis at November, 2006. PPCPs were analyzed by liquid chromatograph coupled with a tandem mass spectrometer (HPLC-MS/MS). The concentration of COD was measured to be 2.37$\sim$19.71 mg/L, which was belong to 4$\sim$5 grade in water quality criteria of lake. Station 2 that there is no pollution in upper stream, was appeared to lower concentration. The concentration of TN and TP, that is cause matter of eutrophication, were found to be 7.78$\sim$35.42 mg/L and 0.08$\sim$0.95 mg/L, respectively, which were exceeding 5 grade in Lake water quality criteria. The 11 kind of PPCPs compounds except levofloxacin and triclosan were detected to Mankyung river. PPCPs concentrations of STP(Sewer Treatment Plant) effluents and aquatic environment in Mankyung river have been detected in the range from dozens of ng/L to hundreds of ${\mu}g/L$ that by order of atenolol, carbamazepine, propranolol, Ibuprofen, erythromycin, ifenprodil, clarithromycin, mefenamic acid, fluconazole, indomethacin, disopyramide. PPCPs concentration of Station 1 and 5, which was influenced by Jeonju STP and Wanju STP, was detected high values. Station 2 that there is no pollution, showed lower values. Station 3 which joined Gosan stream and Jeonju stream and station 4 which influenced by stock wastewater was detected to low values.

• 상하수도학회지
• /
• 제36권2호
• /
• pp.107-119
• /
• 2022

The frequent detection and occurrence of micropollutants (MPs) in aquatic ecosystems has raised public health concerns worldwide. In this study, the behavior of 50 MPs was investigated in three different domestic wastewater treatment plants (WWTPs). Furthermore, the Kruskal-Wallis test was used to assess the geographical and seasonal variation of MPs in the WWTPs. The results showed that the concentrations of 43 MPs ranged from less than 0.1 to 237.6 ㎍ L^-1, while other seven MPs including 17-ethynylestradiol, 17-estradiol, sulfathiazole, sulfamethazine, clofibric acid, simvastatin, and lovastatin were not detected in all WWTPs. Among the detected MPs, the pharmaceuticals such as metformin, acetaminophen, naproxen, and caffeine were prominent with maximum concentrations of 133.4, 237.6, 71.5, and 107.7 ㎍ L^-1, respectively. Most perfluorinated compounds and nitrosamines were found at trace levels of 1.2 to 55.3 ng L^-1, while the concentration of corrosion inhibitors, preservatives (parabens), and endocrine disruptors ranged from less than 0.1 to 4310.8 ng L^-1. Regardless of the type of biological treatment process such as MLE, A2O, and MBR, the majority of pharmaceuticals (except lincomycin, diclofenac, iopromide, and carbamazepine), parabens (except Methyl paraben), and endocrine disruptors were removed by more than 80%. However, the removal efficiencies of certain MPs such as atrazine, DEET, perfluorinated compounds (except PFHxA), nitrosamines, and corrosion inhibitors were relatively low or their concentration even increased after treatment. The results of statistical analysis reveal that there is no significant geographical difference in the removal efficacy of MPs, but there are temporal seasonal variations in all WWTPs.

• Clinical and Experimental Pediatrics
• /
• 제45권9호
• /
• pp.1134-1140
• /
• 2002

목 적: 소아에서 우발사고는 경제 및 문화수준의 향상으로 인한 생활의 기계화와 자동화에 의해 점차 증가하는 추세이며 소아기 사망의 중요한 원인이 되고 있다. 이에 저자들은 응급실을 방문한 우발사고 환아들을 대상으로 상부 위장관이나 기도내 이물흡인과 중독을 중심으로 후향적으로 의무기록을 조사하여 소아 우발사고의 예방대책을 수립하는데 도움이 되고자 본 조사를 시행하였다. 방 법 : 1990년 1월 1일부터 1999년 12월 31일까지만 10년간 서울아산병원 응급실을 방문한 만 15세 미만의 외상, 추락, 화상, 이물흡인 및 중독 환아 6410명을 대상으로 하여 사고의 유형별 분석 및 이물질의 종류, 성과 연령, 위치, 치료 방법에 대하여 병원의 입원기록지를 바탕으로 후향적으로 조사하였다. 결 과 : 1) 사고의 유형별 분포를 보면 외상환아가 5,038례로 가장 많았고 다음이 추락 803례, 화상 353례, 이물 흡인 188례, 중독 28례의 순으로 발생하였고, 남녀비는 1.8 : 1이었다. 2) 이물흡인의 경우 총 188례 중 남녀비는 2 : 1이었으며, 연령별 발생 분포는 6세 이하가 169례(89%)로 가장 많았고 특히 1-2세가 57례(30%)로 많은 분포를 나타내었다. 중독의 경우 남녀비는 1.3 : 1이었고, 연령별 분포는 1-2세가 12례(42%)로 가장 많았고 1세 이하에서 6례(21%), 6세 이상에서 6례(21%)가 관찰되었다. 3) 이물흡인의 위치는 상부 위장관이 112례(59%)로 가장 많은 분포를 보였고, 호흡기관 57례(30%), 외이도가 15례(7%) 순이었다. 상부 위장관 이물의 경우 식도가 69례(61%)로 가장 많았고 위가 43례(38%)를 보였다. 기도내 이물의 경우 우측 및 좌측 주 기관지가 각각 27례(47%)로 동일한 분포를 보였다. 4) 이물의 종류를 보면 상부 위장관의 경우 동전이 65례(58%)로 가장 많았고, 핀이 12례(10.7%), 장난감 및 열쇠가 각각 6례(5.3%), 반지 및 바둑알이 각각 5례(4.5%)였으며, 기도내 이물의 경우 땅콩이 36례(63%)로 가장 많았고, 장난감 부속품이 11례(19%)였다. 5) 이물흡인의 치료 방법으로 상부 위장관 이물의 경우 경성 식도내시경으로 제거된 경우가 60례(54%), 굴곡성 내시경으로 제거된 경우가 29례(26%), 수술을 받은 경우가 7례(6%)였으며, 16례(14%)는 자연 배출되었다. 식도내 이물과 위내 이물 중 핀과 같은 날카로운 경우 진단 즉시 내시경으로 제거하였고, 위내 이물 43례 중 20례는 진단 후 24시간 이내에 제거하였다. 그러나 추적 관찰시 시행한 단순 복부 방사선사진에서 위내 이물이 십이지장을 지난 23례 중 16례(70%)는 2주 이내에 모두 합병증이 없이 자연 배출되었고, 7례(30%)는 장폐쇄 증상 등이 동반되어 수술적으로 제거되었으며 수술 후 합병증은 동반되지 않았다. 기도내 이물의 경우 51례에서 경성 기관지내시경으로 제거되었으나 6례에서는 이미 심한 질식과 뇌손상으로 사망하였다. 6) 중독의 원인별 분포를 보면 약물이 원인인 경우가 14례(50%)였고, 그 중에서 경련성 질환을 가진 환아에서 Carbamazepine이 5례(18%), Valproic acid가 4례(14%)였다. 결 론: 지난 10년간 우발사고의 원인으로 외상이 가장 많았고, 추락, 화상, 이물흡인 그리고 중독의 순이었다. 최근에 이물흡인과 중독이 영유아에서 많이 증가하고 있으며, 특히 기도내 이물흡인의 경우 사망률이 가장 높기 때문에 기도 유지를 위한 적절한 처치가 필요함을 알 수 있다.

• Clinical and Experimental Pediatrics
• /
• 제48권5호
• /
• pp.527-533
• /
• 2005

목 적 : 소아 간질 환아에서 장기간 항경련제를 투여시 저신장, 저칼슘혈증, 골밀도 저하가 올 수 있는 것으로 알려져 있다. 저자들은 골밀도 및 골표지자의 연구를 통해 항경련제 투여 환아의 골대사 질환의 위험을 조기 발견할 수 있는지 알아보고자 하였다. 방 법 : 간질로 단국대학교병원 소아과에서 12개월 이상 항경련제 치료를 받고 있는 환자들 중 5-16세의 환아 30명을 대상으로 2003년 7월부터 2004년 2월 사이에 본 연구를 시행하였다. 대상 환아들을 carbamazepine과 valproic acid를 단독 투여군과 2가지 이상의 항경련제를 병합투여한 군으로 나누었고, 요추부 골밀도, 체질량지수, 골연령 및 골표지자들을 측정한 후, 남녀별, 연령별로 분류하여 대조군과 비교하였다. 결 과 : 총 30명이었으며, 검사 당시 평균연령은 $10.4{\pm}3.1$세(5-16세)이었다. Carbamazpine 단독 투여군 10명, valproic acid 단독 투여군 6명, 2가지 이상의 약물을 투여 받은 복합 투여군이 14명이었고 복합 투여군 중에는 뇌성마비 2명, 소두증 2명, 뇌연화증 1명, 선천성심장병 1명이 포함되었다. 각 투여군 간에는 요추 골밀도, 칼슘, 인, 알칼리성 인산화효소, $25(OH)D_3$, 오스테오칼신, 부갑상선호르몬, deoxypyridinoline, 골연령 등의 차이는 없었다. 남녀별, 연령별로 나누었을 때 5세 및 15세 여아에서 -2.5 SDS 미만의 의미있는 골밀도의 감소를 보였으며, 체질량지수는 5 percentile 미만의 현저한 감소를 보이고 있었고, 골 연령 및 신장도 감소되어 있었다. 이러한 감소를 보인 두 명의 환아 중 5세 환아는 심방중격결손증 및 소두증을 가지고 있었으며 15세 여아는 뇌성마비 및 뇌연화증이 있었고 좌하지 골절의 기왕력이 있었으며 두 환아 모두 2가지 항경련제를 4년 이상 투약 받았다. 골밀도는 체질량지수 및 골연령과 통계적으로 의미있는 양의 상관관계를 보였다. 결 론 : 장기간 항경련제를 복용하는 소아환자들에 있어 특히, 신체활동이 제한되어 있거나 다른 만성질환을 동반한 경우에는 골대사에 대한 세심한 주의가 필요하며 주기적으로 키, 몸무게를 측정하여 체질량지수 및 신장의 SDS를 산출하는 것이 골대사에 대한 간단하면서도 중요한 검사가 될 수 있을 것으로 생각된다.